Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data JUPITER NEUROSCIENCES, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Revenue
0
0.02
Cost of revenue
0
Gross profit
0.02
Research and development
0.95
0.49
2.09
Selling, general and administrative
6.84
General and administrative
2.92
2.6
6.84
Operating expenses
3.87
3.09
8.93
Operating income
-3.87
-3.09
-8.91
Interest expense
0.22
0.25
0.07
Interest income
0
0.01
Other non-operating income
-0.91
0.65
0.26
Net income
-4.78
-2.44
-8.64
EPS, basic
-0.18
-0.08
-0.25
EPS, diluted
-0.18
-0.08
-0.25
Shares, basic (weighted)
26.4
28.8
34.6
Shares, diluted (weighted)
26.4
28.8
34.6
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
0.03
3.77
3.79
Receivables
0
Inventory
0.16
Other current assets
0
0.11
0.11
Total current assets
0.03
4.65
4.82
Lease right-of-use assets
0.12
0.07
0.02
Other non-current assets
0
0
0
Total assets
0.15
6.2
5.56
Accounts payable
0.55
0.4
0.64
Deferred revenue
0
Total current liabilities
5.77
2.01
7.4
Lease liabilities
0.07
0.02
Total liabilities
5.95
2.03
7.4
Paid-in capital
17.8
30.2
32.8
Retained earnings
-23.6
-26
-34.7
Shareholders' equity
-5.8
4.17
-1.83
Total equity
-5.8
4.17
-1.83
Total liabilities and equity
0.15
6.2
5.56
Shares outstanding
26.5
33.1
0.46
Cash flow statement
FY2024
FY2024
FY2025
Net income
-4.78
-2.44
-8.64
Stock-based compensation
1.2
1.84
2.42
Change in receivables
-0
Change in inventory
-0.16
Change in payables
0.16
-0.15
0.24
Cash from operations
-0.48
-3.91
-5.41
Stock issued
0.06
0.15
Cash from financing
0.45
7.65
5.43
Net change in cash
-0.04
3.74
0.02
Interest paid
0.03
0.15
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.67 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-247.4%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-143.9%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-10.3%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
20.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.66x
Current assets / current liabilities.
Quick ratio
0.39x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.39x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$13.00
Cash from operations / diluted weighted shares.
Book value per share
-$0.55
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-447.4%
Net income / market cap (the inverse of P/E).
What was JUPITER NEUROSCIENCES, INC.'s revenue in fiscal 2025?
JUPITER NEUROSCIENCES, INC. reported revenue of $21.8K for fiscal 2025.
Was JUPITER NEUROSCIENCES, INC. profitable in fiscal 2025?
No. It reported a net loss of $8.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.